Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: margie who wrote (5687)	11/20/1998 6:53:00 PM
From: scaram(o)uche	Read Replies (1) of 6136

>> There is no controversy about the side effects of IL-2. Apparently there are less side effects wih IL-2 if administered subcutaneously, than through IV. << I was collaborating with BioTherapeutics (now belly up) of Franklin/Memphis when the first patients were receiving Chiron's IL-2 there. Dosing was iv and experimental. I got to talk to one of the early "success story" patients who had a huge renal Ca that went undetectable. He was enthusiastic, but described a nightmare of side effects that terminated with a skin peel. Not fun...... brave patients.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next